ArticleJournal of neurology2026
Family history of multiple sclerosis and long-term outcomes.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundFamily history is a well-established risk factor for multiple sclerosis (MS), but its influence on disease progression remains unclear. We investigated whether familial MS, including degree of relatedness, is associated with baseline characteristics and disease outcomes.
methodsWe included individuals with incident MS from the Swedish population-based epidemiologic investigation of multiple sclerosis study with longitudinal follow-up through the Swedish MS registry. Participants were categorized as having no family history of MS, first-degree familial MS, or second-/third-degree familial MS. Outcomes included confirmed disability worsening (CDW), progression to Expanded Disability Status Scale milestones 3 and 4, cognitive worsening measured by the symbol digit modalities test, MRI disease activity, and worsening on the Multiple Sclerosis Impact Scale-29. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox regression.
resultsAmong 3,094 participants, 239 (7.7%) reported a first-degree relative with MS and 468 (15.1%) reported a second-/third-degree relative with MS. Baseline characteristics were similar across groups, although HLA-DRB1*15:01 positivity was more common among individuals with first-degree familial MS. No significant associations were observed between familial MS status and disability progression, cognitive decline, MRI disease activity, or patient-reported worsening. Compared with individuals without a known family history of MS, the HR for CDW was 1.06 (95% CI 0.89-1.30) among individuals with first-degree familial MS and 1.04 (95% CI 0.90-1.20) among those with second-/third-degree familial MS.
conclusionsFamily history of MS did not appear to have a substantial prognostic impact on long-term disease outcomes after MS onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.